CD4 and neoplasm: The biomarker analysis showed that PD-L1 combined positive score (CPS), tumor CD68 and CD4 protein levels (representing cell surface protein markers for TAMs), and tumor-infiltrating CD4 T cells could be potential predictive markers for cabozantinib plus durvalumab activity in this setting.